Search Results

Molecular Assemblies, Inc., a pioneer and leader in the field of enzymatic DNA synthesis, announced the launch of its Partnering Program to license Molecular Assemblies’ Fully Enzymatic SynthesisTM technology for onsite synthesis.

Molecular Assemblies, Inc. today announced the addition of two industry leaders to its Commercial-Technology Advisory Board (CTAB), which includes experts in the commercialization of nucleic acid technologies and innovative life science product solutions.

Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with Neomorph to discover and develop molecular glue degraders.

The Swiss pharma is paying $150 million upfront to gain rights to Monte Rosa’s VAV1-targeting molecular glue degraders, led by a Phase I candidate which holds therapeutic promise for immune-mediated diseases.

Assembly Biosciences, Inc. announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a next-generation capsid assembly modulator candidate in development for the treatment of chronic hepatitis B virus infection.

Assembly Biosciences, Inc. today announced that it has closed the issuance of shares of its common stock and warrants to Armistice Capital LLC (“Armistice Capital”), a healthcare-focused institutional investor, and Gilead Sciences, Inc. (“Gilead”), in separate equity financings that have resulted in aggregate gross proceeds to Assembly Bio of approximately $12.6 million, before deducting expenses.

Molecular Templates, Inc. today provided an update on its clinical-stage programs.

Alveo Technologies, Inc., a leader in molecular sensing and diagnostics with its proprietary technology platform, announced the results of rigorous testing that demonstrate the ruggedness of its portable molecular testing platform.

Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, today announced it has shipped the first enzymatically synthesized oligonucleotides to top biotechnology, academic, and synthetic biology researchers, delivered as part of a key customer program.